Danske Bank downgraded Xvivo Perfusion (XVIPF) to Sell from Buy with a price target of SEK 325, down from SEK 560. The firm sees short-term headwinds and a “too rich” valuation.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XVIPF: